Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets

Kangjie Yu; Joseph Rohr; Yang Liu; Mingyang Li; Junpeng Xu; Kaijing Wang; Jia Chai; Danhui Zhao; Yixiong Liu; Jing Ma; Linni Fan; Zhe Wang; Shuangping Guo

doi:10.1016/j.prp.2020.152874

Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets

Pathol Res Pract. 2020 Apr;216(4):152874. doi: 10.1016/j.prp.2020.152874. Epub 2020 Feb 13.

Authors

Kangjie Yu¹, Joseph Rohr², Yang Liu¹, Mingyang Li¹, Junpeng Xu¹, Kaijing Wang¹, Jia Chai¹, Danhui Zhao¹, Yixiong Liu¹, Jing Ma¹, Linni Fan¹, Zhe Wang³, Shuangping Guo⁴

Affiliations

¹ State Key Laboratory of Tumor Biology, Department of Pathology, Xi Jing Hospital, the Fourth Military Medical University, Xi'an, Shaan Xi Province,710032, China.
² Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
³ State Key Laboratory of Tumor Biology, Department of Pathology, Xi Jing Hospital, the Fourth Military Medical University, Xi'an, Shaan Xi Province,710032, China. Electronic address: [email protected].
⁴ State Key Laboratory of Tumor Biology, Department of Pathology, Xi Jing Hospital, the Fourth Military Medical University, Xi'an, Shaan Xi Province,710032, China. Electronic address: [email protected].

PMID: 32088086
DOI: 10.1016/j.prp.2020.152874

Abstract

Triple-negative breast carcinoma (TNBC) is a subtype of breast carcinoma defined by negativity for estrogen receptor (ER) or progesterone receptor (PR) by immunohistochemical analysis and negativity for human epidermal growth factor receptor (Her2) by immunohistochemistry or in situ hybridization. TNBC is clinically marked by its high aggressiveness, particularly poor outcomes including a low survival rate, and the lack of specific and effective treatments. Therefore, new potential targets for the treatment of TNBC must be identified. This review summarizes recent evidence supporting novel targets and possible therapeutic regimens in the treatment of TNBC.

Keywords: Progress in pathophysiology; Signaling pathway; Therapeutic targets; Triple negative breast carcinoma (TNBC).

Publication types

Review

MeSH terms

Female
Humans
Triple Negative Breast Neoplasms / physiopathology*